Treatment of male genital lichen sclerosus with clobetasol propionate and maintenance with either methylprednisolone aceponate or tacrolimus: a retrospective study

References

• Chi CC, Kirtschig G, Baldo M, Brackenbury F, Lewis F, Wojnarowska F. Topical interventions for genital lichen sclerosus. Cochrane Database Syst Rev. 2011;12:CD008240.
   Google Scholar
• Chi CC, Kirtschig G, Baldo M, Lewis F, Wang SH, Wojnarowska F. Systematic review and meta-analysis of randomized controlled trials on topical interventions for genital lichen sclerosus. J Am Acad Dermatol. 2012;67:305–312.
   PubMed Web of Science ®Google Scholar
• Patsatsi A, Kyriakou A, Vavilis D, Mantas A, Patsialas C, Sotiriadis D. A therapeutic approach for female, relapsing genital lichen sclerosus: a single-center study. J Dermatolog Treat. 2012 [Epub ahead of print].
   Google Scholar
• Powell JJ, Wojnarowska F. Lichen sclerosus. Lancet. 1999;353:1777–1783.
   PubMed Web of Science ®Google Scholar
• Tasker GL, Wojnarowska F. Lichen sclerosus. Clin Exp Dermatol. 2003;28:128–133.
   PubMedGoogle Scholar
• Bilenchi R, Poggiali S, De Padova LA, Pisani C, De Paola M, Fimiani M. Human papillomavirus reactivation following topical tacrolimus therapy of anogenital lichen sclerosus. Br J Dermatol. 2007;156:405–406.
   Google Scholar
• Dahlman-Ghozlan K, Hedblad MA, von KG. Penile lichen sclerosus et atrophicus treated with clobetasol dipropionate 0.05% cream: a retrospective clinical and histopathological study. J Am Acad Dermatol. 1999;40:451–457.
   PubMedGoogle Scholar
• Nasca MR, Innocenzi D, Micali G. Penile cancer among patients with genital lichen sclerosus. J Am Acad Dermatol. 1999;41:911–914.
   PubMed Web of Science ®Google Scholar
• Powell J, Robson A, Cranston D, Wojnarowska F, Turner R. High incidence of lichen sclerosus in patients with squamous cell carcinoma of the penis. Br J Dermatol. 2001;145:85–89.
   PubMed Web of Science ®Google Scholar
• von KG, Dahlman-Ghozlan K, Syrjanen S. Potential human papillomavirus reactivation following topical corticosteroid therapy of genital lichen sclerosus and erosive lichen planus. J Eur Acad Dermatol Venereol. 2002;16:130–133.
   PubMedGoogle Scholar
• Wang SH, Chi CC, Wong YW, Salim A, Manek S, Wojnarowska F. Genital verrucous carcinoma is associated with lichen sclerosus: a retrospective study and review of the literature. J Eur Acad Dermatol Venereol. 2010;24:815–819.
   Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–216.
   PubMed Web of Science ®Google Scholar
• Sherman V, McPherson T, Baldo M, Salim A, Gao XH, Wojnarowska F. The high rate of familial lichen sclerosus suggests a genetic contribution: an observational cohort study. J Eur Acad Dermatol Venereol. 2010;24:1031–1034.
   PubMedGoogle Scholar
• Smith YR, Haefner HK. Vulvar lichen sclerosus: pathophysiology and treatment. Am J Clin Dermatol. 2004;5:105–125.
   PubMed Web of Science ®Google Scholar
• Neill SM, Ridley CM. Management of anogenital lichen sclerosus. Clin Exp Dermatol. 2001;26:637–643.
   Google Scholar
• Harrington CI, Dunsmore IR. An investigation into the incidence of auto-immune disorders in patients with lichen sclerosus and atrophicus. Br J Dermatol. 1981;104:563–566.
   PubMed Web of Science ®Google Scholar
• Gao XH, Barnardo MC, Winsey S, Ahmad T, Cook J, Agudelo JD, et al. The association between HLA DR, DQ antigens, and vulval lichen sclerosus in the UK: HLA DRB112 and its associated DRB112/DQB10301/04/09/010 haplotype confers susceptibility to vulval lichen sclerosus, and HLA DRB10301/04 and its associated DRB10301/04/DQB10201/02/03 haplotype protects from vulval lichen sclerosus. J Invest Dermatol. 2005;125:895–899.
   PubMed Web of Science ®Google Scholar
• Marren P, Yell J, Charnock FM, Bunce M, Welsh K, Wojnarowska F, et al. The association between lichen sclerosus and antigens of the HLA system. Br J Dermatol. 1995;132:197–203.
   PubMed Web of Science ®Google Scholar
• Bunker CB. Comments on the British Association of Dermatologists guidelines for the management of lichen sclerosus. Br J Dermatol. 2011;164:894–895.
   PubMed Web of Science ®Google Scholar
• Bunker CB. Male genital lichen sclerosus and tacrolimus. Br J Dermatol. 2007;157:1079–1080.
   Google Scholar
• Goldstein AT, Creasey A, Pfau R, Phillips D, Burrows LJ. A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus. J Am Acad Dermatol. 2011;64:e99–e104.
   PubMedGoogle Scholar
• Fistarol SK, Itin PH. Diagnosis and treatment of lichen sclerosus : an update. Am J Clin Dermatol. 2013;14:27–47.
   PubMed Web of Science ®Google Scholar
• Neill SM, Lewis FM, Tatnall FM, Cox NH. British Association of Dermatologists' guidelines for the management of lichen sclerosus 2010. Br J Dermatol. 2010;163:672–682.
   PubMed Web of Science ®Google Scholar
• Schwegler J, Schwarz J, Eulenburg C, Blome C, Ihnen M, Mahner S, et al. Health-related quality of life and patient-defined benefit of clobetasol 0.05% in women with chronic lichen sclerosus of the vulva. Dermatology. 2011;223:152–160.
   PubMedGoogle Scholar
• Riddell L, Edwards A, Sherrard J. Clinical features of lichen sclerosus in men attending a department of genitourinary medicine. Sex Transm Infect. 2000;76:311–313.
   PubMed Web of Science ®Google Scholar
• Tausch TJ, Peterson AC. Early aggressive treatment of lichen sclerosus may prevent disease progression. J Urol. 2012;187:2101–2105.
   Google Scholar
• Fistarol SK, Itin PH. Anti-inflammatory treatment. Curr Probl Dermatol. 2011;40:58–70.
   Google Scholar
• Ruzicka T, Assmann T, Lebwohl M. Potential future dermatological indications for tacrolimus ointment. Eur J Dermatol. 2003;13:331–342.
   Google Scholar
• Bohm M, Frieling U, Luger TA, Bonsmann G. Successful treatment of anogenital lichen sclerosus with topical tacrolimus. Arch Dermatol. 2003;139:922–924.
   PubMedGoogle Scholar
• Fischer G, Bradford J. Topical immunosuppressants, genital lichen sclerosus and the risk of squamous cell carcinoma: a case report. J Reprod Med. 2007;52:329–331.
   PubMed Web of Science ®Google Scholar
• Bunker CB, Neill S, Staughton RC. Topical tacrolimus, genital lichen sclerosus, and risk of squamous cell carcinoma. Arch Dermatol. 2004;140:1169.
   PubMedGoogle Scholar
• Lewis FM, Neill SM. Safety of calcineurin inhibitors in the management of lichen sclerosis. Br J Dermatol. 2007;156:1389–1390.
   PubMed Web of Science ®Google Scholar
• Hengge UR, Krause W, Hofmann H, Stadler R, Gross G, Meurer M, et al. Multicentre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus. Br J Dermatol. 2006;155:1021–1028.
   PubMed Web of Science ®Google Scholar
• Kim GW, Park HJ, Kim HS, Kim SH, Ko HC, Kim BS, et al. Topical tacrolimus ointment for the treatment of lichen sclerosus, comparing genital and extragenital involvement. J Dermatol. 2012;39:145–150.
   PubMedGoogle Scholar
• Ebert AK, Rosch WH, Vogt T. Safety and tolerability of adjuvant topical tacrolimus treatment in boys with lichen sclerosus: a prospective phase 2 study. Eur Urol. 2008;54:932–937.
   Google Scholar
• Barbagli G, Lazzeri M. Editorial comment on: safety and tolerability of adjuvant topical tacrolimus treatment in boys with lichen sclerosus: a prospective phase 2 study. Eur Urol. 2008;54:937.
   Google Scholar
• Ayhan A, Guven ES, Guven S, Sakinci M, Dogan NU, Kucukali T. Testosterone versus clobetasol for maintenance of vulvar lichen sclerosus associated with variable degrees of squamous cell hyperplasia. Acta Obstet Gynecol Scand. 2007;86:715–719.
   PubMed Web of Science ®Google Scholar
• Simonart T, Lahaye M, Simonart JM. Vulvar lichen sclerosus: effect of maintenance treatment with a moisturizer on the course of the disease. Menopause. 2008;15:74–77.
   PubMed Web of Science ®Google Scholar